海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Premixed Insulin on Top of Metformin in Patients With Type 2 Diabetes and ± Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
- Patients with Type 2 Diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents(OADs) MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Algeria, Argentina, Austria, Bulgaria, Czech Republic, Greece, India, Korea, Republic of, Kuwait, Macedonia, the former Yugoslav Republic of, Mexico, Romania, Saudi Arabia, Serbia, Spain, Sweden, Taiwan, Turkey, United Arab Emirates
- 2018-07-30
Authorised
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Premixed Insulin on Top of Metformin in Patients With Type 2 Diabetes and ± Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
- Patients with Type 2 Diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents(OADs) MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Algeria, Argentina, Austria, Bulgaria, Czech Republic, Greece, India, Korea, Republic of, Kuwait, Macedonia, the former Yugoslav Republic of, Mexico, Romania, Saudi Arabia, Serbia, Spain, Sweden, Taiwan, Turkey, United Arab Emirates
- 2018-06-26
Authorised
- An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)
- Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0 Level: PT Classification code 10014989 Term: Epidermolysis bullosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Australia, Austria, France, Germany, Israel, Italy, Netherlands, United Kingdom, United States
- 2017-11-29
Authorised
- A phase III multi-center, open label, randomised study of optimised imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
- Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) MedDRA version: 19.0 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10009013 Term: Chronic myeloid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Venezuela, Bolivarian Republic of
- 2007-03-14
Authorised
- EHOA: Etanercept as treatment for Hand OsteoArthritis A randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy and the structure modifying properties of etanercept 50/25 mg subcutaneous weekly in patients with eroive osteoarthritis of the interphalangeal finger joints - EHOA
- Patients with erosive inflammatory osteoarthritis of the interphalangeal joints MedDRA version: 9.1 Level: LLT Classification code 10016686 Term: Finger osteoarthritis
- Austria, Netherlands
- 2007-10-17
Authorised
- A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +) - ITEM
- Non-small Cell Lung Cancer
- Austria, Belgium, Germany, United Kingdom
- 2006-07-20
Authorised
- ""Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterferón alfa-2a y ribavirina en sujetos infectados por el genotipo 1 de la hepatitis C que han recidivado tras un tratamiento previo basado en interferón" "A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy" - Promise
- Hepatitis C Virus (HCV) MedDRA version: 12.1 Level: LLT Classification code 10019752 Term: Hepatitis C virus (HCV)
- Austria, Belgium, Italy, Poland, Spain, United Kingdom
- 2010-11-04
Authorised
- A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
- Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) MedDRA version: 20.0 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000013009 MedDRA version: 20.0 Level: PT Classification code 10009013 Term: Chronic myeloid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Venezuela, Bolivarian Republic of
- 2007-03-13
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-05-02
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn's Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)
- Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Austria, Brazil, Croatia, Czech Republic, Germany, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, South Africa, United Kingdom, United States
- 2018-04-19